By Kristin Ryan, EVP, AI Transformation & Acceleration
Cannes Lions has become a major convening space for brand leaders, agencies, platforms, technology companies, creators and media owners. Cannes describes the festival as a place where leading creative work is awarded, thought leaders take the stage, and the industry comes together to exchange ideas and drive growth.
This year's festival:
- Received +20,000 submissions from 92 countries
- Introduced AI craft subcategories
- Added new award integrity standards across categories
- Expanded senior leader forums, including the CEO forum and a new Global CMO forum
The dominant theme from Cannes Lions 2026 is that AI has moved from experimentation to infrastructure. The conversation is no longer simply “Can AI make content faster?” It is now about how AI changes discovery, media, creative workflows, brand visibility, consumer decision-making, agency models, compliance, personalization, commerce and trust.
AI will reshape how patients, caregivers, HCPs and payers find, interpret and act on health information. And Cannes reinforces that while AI can scale content and compress decision journeys, we cannot undervalue the continued importance of human judgment, trust, evidence, empathy and brand integrity.
Key themes from this year:
AI is becoming the new marketing operating layer
AI was not treated as a novelty at Cannes 2026. It was positioned as a structural shift in how brands are found, evaluated, experienced and measured.
OpenAI’s session, “Advertising in the Age of AI,” framed the shift as a move from a media operating model to an intelligence operating model. The session focused on a world where AI becomes the interface through which people search, learn and act, and where brands enter more conversational, interactive, personalized and utility-driven environments.
LinkedIn’s “Winning the AI Discovery Era: Marketing to Minds and Machines” pushed a similar idea: discovery is no longer a linear funnel, but a compressed decision moment shaped by what AI systems can find, summarize and recommend.
Microsoft’s “Marketer Leadership in the AI Economy” extended this into the idea of an “agentic web,” where AI agents increasingly mediate discovery, evaluation and interaction with brands.
Google’s “Project Genie” won the Digital Craft Grand Prix. Cannes described it as work that translated DeepMind frontier research into a functional consumer-facing interface and a platform for imagination. For pharma communicators, this is a reminder that the most celebrated AI work may not look like an ad. It may look like a tool, interface, service, diagnostic support experience, educational system or behavior-change utility.
What this means for us:
Health brands need to prepare for a world where patients and HCPs do not always arrive through a brand site, rep interaction, search ad or linear content journey. They may encounter summarized, AI-mediated answers first. That makes structured, accurate, findable, medically reviewed content more important. Pharma teams should start treating “AI discoverability” as a serious communications requirement: approved claims, plain-language explanations, indication and safety information, FAQs, HCP resources, patient support materials and disease education need to be organized in ways that search systems, answer engines and AI agents can understand without distorting the message.
Cannes is drawing a hard line between AI-enabled creativity and AI-replaced creativity
The festival’s AI conversation was not simply pro-automation. A major theme was that AI can accelerate, analyze and scale creative work, but it cannot replace taste, judgment, cultural fluency, ethics or brand stewardship that people bring to the table.
Google DeepMind CEO Demis Hassabis’ fireside chat, “The Future of Creativity,” focused on the fusion of technology and art, with AI tools positioned as a way to empower artistic expression rather than erase it.
P&G’s Marc Pritchard made the point more bluntly in “Robots Can’t Build Brands,” a session about how data, digital technology and AI are transforming creativity while not sidelining the human insight and craft required to build enduring brands.
R/GA’s “Making Things That Make Things” noted that when anyone can generate endless content, the value moves to creative systems powered by taste, curation and strategic judgment.
Cannes introduced AI Craft subcategories across craft-led Lions to recognize work where human creativity and artificial intelligence come together, with the stated emphasis that AI should serve the idea. This matters because it draws a distinction between AI as a production shortcut and AI as a meaningful creative material. For healthcare, that distinction should become a working principle. AI should be used when it improves clarity, access, personalization, empathy or utility—not simply because it is available.
The introduction of Awards Integrity Standards across all categories is also important in an AI-heavy year. As AI makes it easier to simulate results, generate case-study assets, manipulate visuals or exaggerate impact, credibility in award submissions and public claims becomes more important. For pharma, this is especially relevant. Case studies must be able to withstand scrutiny around outcomes, claims, audience impact, safety, substantiation and real-world deployment.
What this means for us:
In pharma, this distinction is critical. AI can help draft, version, tag, summarize, localize and optimize content, but it cannot be the final arbiter of scientific accuracy, fair balance, claims support, patient empathy or medical appropriateness. The brands that benefit most from AI will not be the ones that simply produce more assets. They will be the ones that build stronger review systems, clearer claim libraries, better modular content operations, stronger medical-legal-regulatory workflows and more disciplined human oversight.
AI is changing not just content production, but brand memory and brand strategy
AI should be framed as a tool for understanding what makes a brand distinctive—not merely a machine for generating new variants. In a crowded environment, the strategic use case may be: What has historically made this brand trusted, recognizable and culturally resonant? What equities should be protected? What patterns should not be lost as teams automate execution?
One of the more interesting AI conversations at Cannes 2026 was less about generative output and more about strategic analysis. Estée Lauder and Meta’s “The Anatomy of an Icon” explored using AI to analyze brand heritage archives and identify emotional signatures, sensory patterns and creative decisions behind iconic ideas.
What this means for us:
This is highly relevant for mature pharma brands, vaccines, OTC brands and disease-awareness platforms. Many have years of patient stories, HCP insights, adherence research, educational assets, support program learnings and market research. AI can help mine those archives for themes and unmet needs. But the work must be governed carefully: patient privacy, consent, de-identification, claims boundaries and bias controls matter. The best use case is not “make the AI invent our next campaign.” It is “help us understand what patients, caregivers and HCPs have consistently needed from us—and where our communications have or have not earned trust.”
Cannes is expanding the definition of creativity from campaigns to systems
The new Creative Brand Lion that Cannes is rewarding brands not only for individual campaigns, but for building repeatable creative capability.
The inaugural Creative Brand Lion went to AB InBev’s “Creativity at Scale,” with Cannes describing the category as one that recognizes systems, cultures and capabilities that make world-class marketing repeatable.
Adobe described Cannes as a place where creativity, marketing and AI converge, and showcased how Firefly, Frame.io and Creative Cloud powered a connected creative system for its own festival presence. Adobe’s Cannes activation included AI-personalized experiences such as the Adobe Boutique and Firefly Camera, while its broader messaging emphasized that creativity is increasingly becoming infrastructure.
What this means for us:
The practical lesson is to stop treating AI as a side experiment run by innovation teams. For healthcare brands, the opportunity is to build a governed creative operating model: modular content, approved claims, reusable safety language, channel-specific templates, accessibility standards, inclusive imagery guidance, escalation protocols, social listening guardrails and analytics loops. AI can make that system faster, but the strategic value comes from making it safer, more consistent and more responsive.
AI-mediated discovery is colliding with community validation
Consumers may increasingly use AI to get answers, then use communities to validate whether those answers feel real, trustworthy and experience-based. For health information, that behavior already exists: patients often compare formal medical information with lived experience from peers, forums and social platforms.
Reddit used Cannes 2026 to announce new advertising tools powered by Reddit Community Intelligence, which Reddit describes as drawing on more than 25 billion posts and comments. The new tools included a free-form ad generator, tailored creative assets, Redditor Highlights and Shopping Listing Ads.
What this means for us:
Healthcare communicators need to understand both the opportunity and the risk. Communities can reveal unmet needs, language gaps, misinformation, emotional barriers and support needs. But pharma brands must approach community-driven insights with strict guardrails around privacy, adverse event monitoring, off-label discussion, misinformation correction and non-promotional engagement. AI can help identify patterns, but human review is essential before those insights become strategy or content.
Cannes Lions 2026 made one thing clear
AI is no longer a side conversation in marketing. It is becoming part of the creative, media, commerce and discovery infrastructure. But the festival is also reinforcing the limits of automation. Combining AI-enabled speed with human judgment, cultural intelligence, operational discipline and trust will be the key to success in this environment.
For us, the mandate is sharper: use AI to make health information more accessible, useful and responsive—but never at the expense of scientific accuracy, patient dignity, privacy, fair balance or credibility. Cannes’ 2026 signal is not “AI replaces creativity.” It is that AI raises the bar for what responsible creativity must become.
At Inizio Evoke, we are taking a Human + AI approach that reflects a broader shift across healthcare commercialization. We help organizations connect data, technology, AI, and expertise to drive Intelligent Commercialization™—empowering better decisions, stronger engagement, and greater impact at every stage of the journey.
Interested in hearing more? Connect with us here.